Search Results - Abbazio, C.

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY

    FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY by Ghia, P., Allan, J. N., Siddiqi, T., Wierda, W. G., Tam, C. S., Moreno, C., Tedeschi, A., Szafer‐Glusman, E., Zhou, C., Abbazio, C., Dean, J. P., Szoke, A., Barr, P. M.

    Published in Hematological oncology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Ibrutinib (Ibr) for treatment of relapsed‐refractory (R/R) chronic lymphocytic leukemia (CLL): a matching‐adjusted indirect comparison of 3 randomized phase 3 trials

    Ibrutinib (Ibr) for treatment of relapsed‐refractory (R/R) chronic lymphocytic leukemia (CLL): a matching‐adjusted indirect comparison of 3 randomized phase 3 trials by Ghia, P., Munir, T., Burger, J., Seymour, J. F., Rogers, K., Huang, H., Moreno, C., Neumayr, L., Abbazio, C., Sharman, J.

    Published in Hematological oncology
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

    17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Ghia, P, Munir, T, Burger, J, Seymour, J F, Rogers, K, Huang, H, Moreno, C, Neumayr, L, Abbazio, C, Sharman, J

    Published in Hematological oncology
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

    Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Match... by Burger, Jan A., Kay, Neil E., Allan, John N., Barr, Paul M, Barrientos, Jacqueline C., Owen, Carolyn, Wang, Victoria, Huang, Hsin-Hui, Neumayr, Lynne, Abbazio, Christopher, Krigsfeld, Gabriel S., Mody, Sneh, Ghia, Paolo, Shanafelt, Tait D.

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years

    Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched P... by Ghia, Paolo, Owen, Carolyn, Barrientos, Jacqueline C., Barr, Paul M., Mato, Anthony R., Shi, Chunxue, Szoke, Anita, Abbazio, Chris, Krigsfeld, Gabriel S., Burger, Jan A.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

    Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia by Allan, John N, Flinn, Ian W, Siddiqi, Tanya, Ghia, Paolo, Tam, Constantine S, Kipps, Thomas J, Barr, Paul M, Elinder Camburn, Anna, Tedeschi, Alessandra, Badoux, Xavier C, Jacobs, Ryan, Kuss, Bryone J, Trentin, Livio, Zhou, Cathy, Szoke, Anita, Abbazio, Christopher, Wierda, William G

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis

    First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pool... by Ghia, Paolo, Owen, Carolyn, Allan, John N., Barrientos, Jacqueline C., Barr, Paul M., Shi, Chunxue, Szoke, Anita, Abbazio, Christopher, Krigsfeld, Gabriel S., Burger, Jan A.

    Published in HemaSphere
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: